S&C Advises MediLink on Exclusive Licensing Agreement with Roche
In order to develop and market YL201, an experimental novel antibody-drug conjugate (ADC) asset that targets B7H3 across various solid tumor types, MediLink Therapeutics and Roche have signed a new partnership and exclusive licensing agreement.